Matrix metalloproteinase-10: a novel biomarker for idiopathic pulmonary fibrosis

Akihiko Sokai1, Tomohiro Handa1*, Kiminobu Tanizawa2, Toru Oga3, Kazuko Uno3, Tatsuaki Tsuruyama4, Takeshi Kubo5, Kohei Ikezoe1, Yoshinari Nakatsuka1, Kazuya Tanimura1, Shigeo Muro1, Toyohiro Hirai1, Sonoko Nagai6, Kazuo Chin2 and Michiaki Mishima1

Abstract

Background: Matrix metalloproteinases (MMPs) are believed to be involved in the pathogenesis of idiopathic pulmonary fibrosis (IPF), and MMP-7 has been described as a useful biomarker for IPF. However, little is known regarding the significance of MMP-10 as a biomarker for IPF.

Methods: This observational cohort study included 57 patients with IPF. Serum MMPs were comprehensively measured in all patients, and the relationships between these markers and both disease severity and prognosis were evaluated. Bronchoalveolar lavage fluid (BALF) MMP-7 and -10 levels were measured in 19 patients to investigate the correlation between these markers and their corresponding serum values. Immunohistochemical staining for MMP-10 was also performed in IPF lung tissue.

Results: Serum MMP-7 and -10 levels correlated significantly with both the percentage of predicted forced vital capacity (\(\rho = -0.31\), \(p = 0.02\) and \(\rho = -0.34\), \(p < 0.01\), respectively) and the percentage of predicted diffusing capacity of the lung for carbon monoxide (\(\rho = -0.32\), \(p = 0.02\) and \(\rho = -0.43\), \(p < 0.01\), respectively). BALF MMP-7 and -10 levels correlated with their corresponding serum concentrations. Only serum MMP-10 predicted clinical deterioration within 6 months and overall survival. In IPF lungs, the expression of MMP-10 was enhanced and localized to the alveolar epithelial cells, macrophages, and peripheral bronchiolar epithelial cells.

Conclusions: MMP-10 may be a novel biomarker reflecting both disease severity and prognosis in patients with IPF.

Keywords: Matrix metalloproteinase-10, Idiopathic pulmonary fibrosis, Biomarker

Background

Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic pulmonary disease with a median survival of 3 to 5 years [1]. The clinical course of IPF is variable and unpredictable [1–3]. Because survival prediction requires both a large population and a long follow-up period, surrogate endpoints, such as declines in forced vital capacity (FVC) and diffusing capacity of the lung for carbon monoxide (DL\(_{\text{CO}}\)), are often used as primary endpoints in clinical studies instead of survival [4, 5]. Regarding serum biomarkers, none have been established as a widespread clinical marker for IPF [6, 7]. However, previous studies have suggested that biomarkers, such as Krebs von den lungen-6 [8], surfactant protein-A (SP-A) [9], CC chemokine ligand 18 [10], and matrix metalloproteinase (MMP)-7 [11], may serve as prognostic biomarkers for IPF.

MMPs have also been evaluated as biomarkers for IPF. MMPs are a family of proteinases whose active sites contain zinc. MMPs play a major role in the degradation and remodeling of the extracellular matrix (ECM), which consists primarily of glycoproteins, including collagens, proteoglycans, and fibronectin. MMPs also regulate multiple functions, such as cell proliferation, adhesion, migration, differentiation, and apoptosis, and play a pivotal role in the pathogenesis of IPF [12]. It has been reported that MMP-1, -2, and -7 are elevated in the serum and that MMP-3, -8, and -9 are elevated in the bronchoalveolar lavage fluid (BALF) in patients with IPF [2, 13, 14].
MMP-7 is one of the most extensively investigated MMPs in IPF. MMP-1 and -7 may be diagnostic biomarkers that distinguish IPF from other chronic lung diseases such as chronic obstructive pulmonary disease and sarcoidosis [15]. Previous studies have also demonstrated that serum MMP-7 correlates with both FVC and DL\textsubscript{CO}, and is associated with survival in patients with IPF [11, 15], suggesting that MMP-7 may be a useful biomarker. Recently, however, it has been reported that not only MMP-7 but also other MMPs may play a significant role in the pathogenesis of IPF [13, 16].

As is the case with other MMPs, MMP-10 also plays a significant role in the degradation and remodeling of the ECM during tissue repair and vascular remodeling [17, 18], which suggests that MMP-10 is also an IPF biomarker candidate. However, in previous studies that screened serum MMPs in IPF, MMP-10 was not included in the analyses [11, 15]. Therefore, little is known regarding the role of MMP-10 in IPF. In the present study, serum MMPs, including MMP-10, were comprehensively measured in patients with IPF, and their relationships with disease severity, short-term deterioration of pulmonary function, and overall survival were investigated.

**Methods**

**Study population**

This was an observational cohort study that enrolled 57 consecutive patients with IPF who visited the Department of Respiratory Medicine at Kyoto University Hospital. The diagnosis of IPF was made according to the diagnostic criteria for IPF [1]. Patients who had active malignant disease or whose forced expiratory volume in one second (FEV\textsubscript{1})/FVC was <70 % were excluded. The day of serum sampling was set as the baseline, and the patients were prospectively evaluated for clinical deterioration every 6 months from the baseline. Fifteen age- and sex-matched healthy volunteers without lung disease were recruited as healthy controls. Twenty patients with chronic obstructive pulmonary disease (COPD) were also recruited as disease controls. A diagnosis of COPD was made according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria [19]. The present study was approved by the Ethics Committee of Kyoto University, and informed consent was obtained from all patients.

**Physiological measurements and bronchoalveolar lavage**

The pulmonary function test (PFT) [20], the 6-minute walk test (6MWT) [21], and the arterial blood gas (ABG) while breathing room air and bronchoalveolar lavage (BAL) [22, 23] were performed according to published guidelines.

**MMP analysis**

Serum and BALF samples were centrifuged immediately following sampling, and the supernatants were stored at -80 °C until needed for analysis. Serum MMP-1, -2, -3, -7, -8, -9, -10, -12, and -13 and BALF MMP-7 and -10 were analyzed using the Bio-Plex Pro Human MMP Panel (Bio-Rad Laboratories, Hercules, CA, USA). Serum samples were quantified according to the manufacturer’s instructions using the Bio-Plex 200, a multiplex cytokine array system. BALF samples and their standards were diluted using bovine serum albumin-phosphate-buffered saline.

**Outcome evaluations**

The outcome evaluations included clinical deterioration within 6 months from baseline and overall survival. Clinical deterioration was defined as a composite outcome consisting of admission due to respiratory failure, death, ≥10 % decline in the percentage of predicted FVC (%FVC), or ≥15 % decline in the percentage of predicted DL\textsubscript{CO} (%DL\textsubscript{CO}). We analyzed whether MMPs were associated with clinical deterioration and overall survival in patients with IPF.

**MMP-10 immunostaining**

Lung tissue specimens obtained from 4 patients with IPF were used for immunohistochemical staining, which was performed on 5-μm paraffin-embedded sections of lung tissue to identify MMP-10-expressing sites using the standard streptavidin-biotin-peroxidase complex method. For antigen retrieval, slides were immersed in citrate buffer and heated in a microwave oven. A rabbit anti-human MMP-10 antibody (Abcam, Cambridge, MA, USA) was applied as a primary monoclonal antibody (1:500 dilution). Positive staining was visualized using 3,3’-Diaminobenzidine. A pathologist evaluated the localization of MMP-10 expression in IPF lung tissue and compared the results with control lung specimens, which were obtained from normal areas distant from the lesions caused by surgically diagnosed organizing pneumonia (OP).

**Statistical analyses**

Statistical analyses were performed using JMP 10.0 (SAS Institute Inc., Cary, NC, USA). Comparisons were performed using Fisher’s test, the Mann-Whitney U test, or the Steel-Dwass test, where appropriate. Correlations between variables were evaluated using Spearman’s rank correlation coefficient. A logistic analysis was used to predict clinical deterioration within 6 months. To identify the factors predictive of mortality, we used a Cox proportional hazards model. A receiver operating characteristic (ROC) analysis of serum MMP-10 was performed to determine the threshold for predicting clinical deterioration. All analyses were considered statistically significant when \( p < 0.05 \).
Results

Patient characteristics
Fifty-seven patients with IPF were recruited; all patient characteristics are shown in Table 1. Ten (17.5%) patients were diagnosed by histological confirmation of the usual interstitial pneumonia (UIP) pattern, whereas the other patients were diagnosed based on a definite UIP pattern on high-resolution computed tomography. The mean age of the patients with IPF was 69.4 years, and 51 (89.5%) patients were male, whereas the mean age of patients with COPD or healthy controls was 70.8 and 65.9 years, respectively. All but one patient with COPD (95.0%) and all healthy controls were male. No significant difference was observed in age and gender ratios between IPF and COPD nor between IPF and healthy controls (Table 1). All patients with COPD and seven control subjects (46.7%) had current or former history of smoking. Twenty-five (43.9%) patients underwent BAL. Three patients had a history of malignant disease: 1 patient had breast cancer, 1 patient had prostate cancer, and another patient had colorectal cancer. No patients suffered disease recurrence over the more than 3 years following their last treatments. Thirteen patients were treated at baseline with prednisolone, an immunosuppressant, or pirfenidone (Additional file 1: Table S1).

Serum and BALF MMPs in IPF
The serum and BALF concentrations are presented in Table 2. MMP-13 was excluded from the analysis because its mean concentration was under the limit of determination in both patient groups and controls. Serum MMP-1 \((p < 0.01)\), MMP-2 \((p = 0.03)\), MMP-7 \((p < 0.01)\), MMP-8 \((p = 0.01)\), MMP-10 \((p < 0.01)\), and MMP-12 \((p < 0.01)\) concentrations were significantly elevated in patients with IPF compared with controls, whereas serum MMP-2 \((p < 0.01)\), MMP-7 \((p < 0.01)\), MMP-9 \((p = 0.03)\), MMP-10 \((p < 0.01)\), and MMP-12 \((p = 0.01)\) concentrations were significantly elevated in patients with IPF compared with COPD patients.

Correlation between serum MMPs and disease severity
The correlation between pulmonary function and MMPs is shown in Table 3. There were significant correlations between MMP-7 and the PFT indices, including %FVC and %DL\(_{CO}\) \((\rho = -0.31, p = 0.02 \text{ and } \rho = -0.32, p = 0.02, \text{ respectively})\). There were also significant correlations between MMP-10 and %FVC and %DL\(_{CO}\) \((\rho = -0.34, p < 0.01 \text{ and } \rho = -0.43, p < 0.01, \text{ respectively})\). There were significant correlations noted between MMP-10 and the 6-minute walk distance \((\rho = -0.38, p < 0.01)\), as well as between MMP-10 and minimum oxygen saturation \((\text{SpO}_2)\) during the 6MWT \((\rho = -0.42, p < 0.01)\). Only MMP-10 correlated significantly with the partial pressure of oxygen \((\rho = -0.32, p = 0.02)\).

Correlation between serum and BALF MMPs
Based on the MMP results and their relationship with disease severity, the BALF concentrations of MMP-7 and -10 were measured. Among the 25 patients who underwent BAL, serum and BALF MMP measurements were simultaneously performed in 19 patients to investigate potential correlations. Significant correlations were observed between serum and BALF concentrations of MMP-7 and MMP-10 \((\rho = 0.64, p < 0.01 \text{ and } \rho = 0.47, p = 0.04, \text{ respectively})\). We also examined 25 BALF samples from the patients who underwent both BAL and PFT within a 1-month interval. BALF MMP-10 correlated significantly with %FVC and %DL\(_{CO}\) in patients with IPF.

Table 1: Patient characteristics

|                | IPF \((n = 57)\) | COPD \((n = 20)\) | Control \((n = 15)\) | p-value | p-value | p-value |
|----------------|-----------------|----------------|----------------|---------|---------|---------|
| Age, years     | 69.4 ± 8.5      | 70.8 ± 7.1     | 65.9 ± 7.9     | NS      | NS      | NS      |
| Gender, male   | 51 (89.5)       | 19 (95.0)      | 15 (100)       | NS      | NS      | NS      |
| Current or former smoker | 53 (93.0)       | 20 (100)       | 7 (46.7)       | <0.001  | NS      | <0.001  |
| Patients who underwent BAL | 25 (43.9)       | –              | –              | –       | –       | –       |
| Patients who underwent SLB | 10 (17.5)       | –              | –              | –       | –       | –       |
| FVC, % predicted | 84.2 ± 21.3     | 93.3 ± 20.1    | –              | NS      | –       | –       |
| DL\(_{CO}\), % predicted | 43.7 ± 14.2     | 56.6 ± 17.5    | –              | 0.004   | –       | –       |
| 6MWD, m        | 454 ± 108       | –              | –              | 85.7 ± 8.4 | – | – |
| Minimum SpO\(_2\) during 6MWT, % | 82.6 ± 13.1 | – | – | – | – | – |

The data are presented either as the number (%) or mean ± standard deviation.

IPF idiopathic pulmonary fibrosis, COPD chronic obstructive pulmonary disease, NS not significant, BAL bronchoalveolar lavage, BALF bronchoalveolar lavage fluid, SLB surgical lung biopsy, FVC forced vital capacity, DL\(_{CO}\) diffusing capacity of the lung for carbon monoxide, 6MWD 6-minute walk distance, SpO\(_2\) oxygen saturation, 6MWT 6-minute walk test, PaO\(_2\) partial pressure of oxygen.
%DLCO ($\rho = -0.46$, $p = 0.02$ and $\rho = -0.44$, $p = 0.03$, respectively), whereas BALF MMP-7 correlated significantly with only %DLCO ($\rho = -0.54$, $p < 0.01$).

**Relationship between MMPs and clinical deterioration or survival**

The median follow-up time from baseline was 459 days (range, 12–1853 days). Fourteen patients deteriorated clinically within 6 months; 2 died due to an acute exacerbation (AE), and 9 exhibited declines in pulmonary function. Furthermore, 3 patients were admitted due to respiratory failure: 2 suffered from chronic respiratory failure, and 1 suffered from a respiratory infection. The causes of death at more than 6 months following baseline included 3 cases of AE, 2 cases of chronic respiratory failure, 1 case of acute lung injury due to pulmonary infection, 1 case of lung cancer, 1 case of sepsis, and 1 case without a clear diagnosis. Logistic analyses for clinical deterioration within 6 months revealed that serum MMP-10 was a significant predictor of clinical deterioration, as were %FVC and %DLCO (Table 4A). A survival analysis performed using a Cox proportional hazard model demonstrated that serum MMP-10, as well as %FVC and %DLCO, was a significant predictor of mortality among patients with IPF (Table 4B). Serum MMP-10 was a significant predictor of clinical deterioration and mortality, even when the patients treated at baseline were excluded (Additional file 1: Table S2). In contrast, serum and BALF MMP-7 were not predictors of either clinical deterioration within 6 months or mortality.

### Table 2 Serum and BALF MMP concentrations

|                | IPF (n = 57) | COPD (n = 20) | Control (n = 15) | p-value | p-value | p-value |
|----------------|-------------|---------------|-----------------|---------|---------|---------|
| Serum          |             |               |                 |         |         |         |
| MMP-1, ng/mL   | 1.52 ± 1.36 | 0.95 ± 0.74   | 0.60 ± 0.58     | 0.005   | NS      | NS      |
| MMP-2, ng/mL   | 73.5 ± 60.8 | 27.6 ± 11.8   | 41.3 ± 40.6     | 0.034   | <0.001  | NS      |
| MMP-3, ng/mL   | 8.43 ± 10.5 | 4.54 ± 2.26   | 3.78 ± 3.00     | NS      | NS      | NS      |
| MMP-4, ng/mL   | 8.39 ± 4.32 | 1.72 ± 0.65   | 2.14 ± 1.41     | <0.001  | <0.001  | NS      |
| MMP-8, ng/mL   | 1.43 ± 1.50 | 0.80 ± 0.62   | 0.47 ± 0.51     | 0.012   | NS      | NS      |
| MMP-9, ng/mL   | 38.7 ± 26.8 | 23.3 ± 15.7   | 25.9 ± 24.0     | NS      | 0.030   | NS      |
| MMP-10, ng/mL  | 1.18 ± 0.83 | 0.16 ± 0.18   | 0.18 ± 0.18     | <0.001  | <0.001  | NS      |
| MMP-12, ng/mL  | 0.31 ± 0.23 | 0.17 ± 0.11   | <0.1a           | <0.001  | 0.013   | <0.001  |
| MMP-13, ng/mL  | <0.1a       | <0.1a         | <0.1a           |         |         |         |
| KL-6, U/mL     | 1084.2 ± 724.4 | –   | –               |         |         |         |
| SP-D, ng/mL    | 300.4 ± 223.7 | –   | –               |         |         |         |
| BALF           |             |               |                 |         |         |         |
| MMP-7, ng/mL   | 9.6 ± 10.7 | –              | –               |         |         |         |
| MMP-10, ng/mL  | 0.10 ± 0.09 | –              | –               |         |         |         |

The data are presented as the mean ± standard deviation.

IPF idiopathic pulmonary fibrosis, COPD chronic obstructive pulmonary disease, NS not significant, KL-6 Krebs von den lungen-6, SP-D surfactant protein-D, BALF bronchoalveolar lavage fluid.

*a The mean is under the limit of determination.

### Table 3 Correlations between function measurements and serum matrix metalloproteinases in IPF

|                | MMP-1 | MMP-2 | MMP-3 | MMP-7 | MMP-8 | MMP-9 | MMP-10 | MMP-12 |
|----------------|-------|-------|-------|-------|-------|-------|--------|--------|
| %FVC           | –     | –     | –     | –0.308* | –     | –     | –0.344† | –      |
| %DLCO          | –     | –     | –0.251 | –     | –0.316† | –     | –0.434† | –      |
| 6MWD           | –     | –0.355† | –     | –     | –0.228 | –     | –0.384† | –0.309a |
| Minimum SpO2 during the 6MWT | –     | –0.235 | –0.261 | –     | –     | –0.416† | –      |
| PaO2 in room air | –     | –     | –     | –     | –     | –     | –0.318† | –      |

The data are shown as Spearman’s $\rho$ when the $p$-value $< 0.10$.

IPF idiopathic pulmonary fibrosis, MMP matrix metalloproteinase, %FVC percentage of predicted forced vital capacity, %DLCO percentage of predicted diffusing capacity of the lung for carbon monoxide, 6MWD 6-minute walk distance, SpO2 oxygen saturation, 6MWT 6-minute walk test, PaO2 partial pressure of oxygen.

*MMP-13 was excluded from the analysis.

†$p < 0.05$, †$p < 0.01$
Table 4 Univariate analyses utilized to predict clinical deterioration and mortality

|                          | Odds ratio | 95 % CI      | p-value |
|--------------------------|------------|--------------|---------|
| %FVC                     | 0.959      | 0.922–0.992  | 0.014   |
| %DLCO                    | 0.903      | 0.824–0.964  | <0.001  |
| Serum MMP-7              |            |              | 0.483   |
| Serum MMP-10             | 2.716      | 1.184–7.830  | 0.017   |
| BALF MMP-7               | NA         |              |         |
| BALF MMP-10              | NA         |              |         |

The odds ratio and hazard ratio are shown when p < 0.10
CI confidence interval, %FVC percentage of predicted forced vital capacity, %DLCO percentage of predicted diffusing capacity of the lung for carbon monoxide, MMP matrix metalloproteinase, BALF bronchoalveolar lavage fluid, NA not available

We performed an ROC analysis to determine the optimal cut-off value of serum MMP-10 for predicting clinical deterioration. The curve had an AUC of 0.741 and a cut-off value of 0.986 ng/μL. When 1.0 ng/μL was set as the threshold, patients with higher values had a significantly higher frequency of clinical deterioration within 6 months compared with patients with lower values (p = 0.01). Furthermore, the mortality of the patients with higher serum MMP-10 values was significantly higher than patients with lower values (log rank test; p = 0.049).

Immunohistochemistry

Immunohistochemical staining for MMP-10 was performed in IPF lung tissue. The expression of MMP-10 was localized primarily to the alveolar macrophages, alveolar epithelial cells, and peripheral bronchiolar epithelial cells in IPF lung tissue (Fig. 1). Positive immunostaining for MMP-10 was observed in both macrophages and alveolar epithelial cells in control lung tissue. However, the number of positive cells was reduced, and the signal intensity was weaker in control lung tissue compared with IPF lung tissue.

Discussion

In the present study, several MMPs, including MMP-10, were significantly elevated in the sera of the patients with IPF compared with the patients with COPD and controls. MMP-10 and -7 correlated significantly with several physiological indices, including %FVC and %DLCO. Furthermore, a higher serum MMP-10 level was associated with both clinical deterioration within 6 months and overall survival. In IPF lungs, MMP-10 was expressed in alveolar macrophages and epithelial cells.

MMPs reportedly play an important role in the pathogenesis of IPF [13]. Previous studies have demonstrated that both BALF and serum MMP-1 were elevated in IPF [14, 15]. The biological roles of MMP-1 suggest that it may play an important role in the pathogenesis of IPF [13, 24]. MMP-3-knockout mice and MMP-7-knockout mice do not develop pulmonary fibrosis induced by bleomycin [25, 26], suggesting that MMP-3 and -7 may also act as mediators of pulmonary fibrosis. Indeed, MMP-1 and -7 were also increased in the patients with IPF compared with controls in the present study.

In previous studies, however, few MMPs reportedly correlated with disease severity and prognosis despite their possible roles in the pathogenesis of IPF. Serum MMP-7 concentrations were elevated in patients with subclinical interstitial lung disease (ILD) and correlated negatively with %FVC and %DLCO, whereas no significant correlation was noted between serum MMP-1 and pulmonary function [15]. High levels serum MMP-7 and SP-A may predict shorter survival in patients with IPF [27]. In the present study, we demonstrated a correlation between MMP-7 and pulmonary function, including %FVC and %DLCO, that was consistent with the findings of the previous studies. Furthermore, we observed that serum MMP-10 correlated more significantly with disease severity and prognosis in patients with IPF compared with MMP-7.

MMP-10, like MMP-3 and -11, is categorized into stromelysins and degrades a variety of ECM proteins, including proteoglycans, laminin, fibronectin, gelatins, and collagen types III, IV, V, and IX [18, 28, 29]. MMP-10 activates other MMPs, including proMMP-1, -7, -8, and -9 [17, 30]. MMP-10 expression is observed in injured and remodeling tissues as well as in various types of cells, including the keratinocytes present in skin wounds, injured colonic tissue, and different cells in injured liver [18, 31, 32]. MMP-10 is one of the most well-known MMPs involved in the pathogenesis of carcinomas. Elevated levels of MMP-10 protein have been observed in tumors, including non-small cell lung cancer [33], head and neck squamous cell carcinoma [34], bladder transitional cell carcinoma [35], epithelial skin cancer [36], renal cell carcinoma [37], and colon adenocarcinoma [38].

In experimental models, MMP-10 was elevated via exposure to cerium oxide or silica [39, 40]. A previous study evaluating the degree of pulmonary fibrosis induced by ultrafine amorphous silica also demonstrated that the expression of MMP-10 was associated with pulmonary fibrosis [41]. Transforming growth factor-β...
(TGF-β) is elevated in IPF and exerts profibrotic effects, such as fibroblast differentiation, suppression of myofibroblast apoptosis, ECM induction, and regulation of the balance between MMPs and tissue inhibitors of MMPs [42, 43]. Furthermore, TGF-β up-regulates several MMPs, including MMP-10, in epithelial cells [44, 45]. Therefore, pulmonary fibrosis may be induced by TGF-β through several pathways, including MMP-10. Taken together, MMP-10 may be involved in the pathogenesis of pulmonary fibrosis, as with other MMPs, such as MMP-1 and -7.

We observed that in human fibrotic lungs, the expression of MMP-10 was localized to the alveolar epithelial cells, macrophages, and peripheral bronchiolar epithelial cells. MMP-10 reportedly localized to fibrotic regions and alveolar macrophages in cerium oxide-treated lungs and silica-induced pulmonary fibrosis [39, 40]. However, the localization of MMP-10 has not been investigated in IPF. Most MMPs, including MMP-1, -2, -7, and -9, are expressed in alveolar epithelial cells, whereas other MMPs, including MMP-2 and -9, may be found in the fibroblastic foci in IPF [2]. Immunohistochemical results and the significant correlation between serum and BALF MMP-10 observed in the present study suggest that serum MMP-10 in IPF is derived from the epithelial cells and macrophages in the lungs.

Despite a more significant correlation of serum MMP-10 with disease severity and prognosis compared with other MMPs, serum concentrations of MMP-10 were lower than many other MMPs in IPF. Although the reason was unclear, the abundant MMP-10 expression in IPF lungs visualized by immunological staining and the significant association between serum MMP-10 and clinical features may suggest that MMP-10 plays a significant role in the pathogenesis of IPF.

There were some limitations to the present study. First, the number of patients was small. Additional prospective studies with larger numbers of patients are necessary to validate the role of MMP-10 as a biomarker for IPF. Second, we did not investigate MMPs in other ILDs, such as nonspecific interstitial pneumonia, connective tissue disease-associated ILD, and OP. MMP-7 is reportedly elevated in other ILDs, such as cryptogenic OP and systemic sclerosis-associated ILD [46–48]; therefore, the up-regulation of MMP-10 may not be specific to IPF. Third, some patients had already been treated with prednisolone, an immunosuppressant, or pirfenidone at baseline. Pirfenidone, an antifibrotic agent that suppresses TGF-β, may affect the expression of MMPs, including MMP-10 [49]. However, the prognostic significance of serum MMP-10 persisted after excluding the treated patients.

We concluded that MMP-10 is a novel biomarker for IPF, correlates with disease severity, and predicts disease progression. Additional studies are necessary to elucidate the functional role of MMP-10 and other MMPs in the pathogenesis of IPF.
Additional file

Additional file 1: Table S1. Treatment for IPF at baseline. Table S2. Univariate analyses utilized to predict clinical deterioration and mortality when 13 treated patients with IPF were excluded. (DOCX 24 kb)

Abbreviations
IPF: idiopathic pulmonary fibrosis; FVC: forced vital capacity; DLCO: diffusing capacity of the lung for carbon monoxide; SP-A: surfactant protein-A; MMP: matrix metalloproteinase; ECM: extracellular matrix; BALF: bronchoalveolar lavage fluid; FEV1: forced expiratory volume in one second; COPD: chronic obstructive pulmonary disease; GOLD: Global Initiative for Chronic Obstructive Lung Disease; PFT: pulmonary function test; 6MWT: 6-minute walk test; ABG: arterial blood gas; BAL: bronchoalveolar lavage; %FVC: percentage of predicted FVC; %DLCO: percentage of predicted DLCO; OP: organizing pneumonia; ROC: receiver operating characteristic; UIP: usual interstitial pneumonia; SpO2: oxygen saturation; AE: acute exacerbation; IILD: interstitial lung disease; TGF-β: transforming growth factor-β.

Competing interests
AS has no conflicts of interest. KT, TO, and KC belong to the Department of Respiratory Care and Sleep Control Medicine which is funded by endowments from Philips-Respironics, Teijin Pharma, Fukuda Denshi, and Fukuda Lifetec Keigji to Kyoto University, but they have no other conflicts of interest. All other co-authors have no conflicts of interest.

Authors’ contributions
TH had full access to all of the study data and assumes responsibility for both the integrity of the data and the accuracy of the analysis; AS contributed to the data analysis; AS and TH drafted the manuscript; AS, TH, KTanizawa, KI, and YN contributed to the study design; AS, TH, KTanizawa, KI, YN, and KTanamura contributed to data collection; AS and KU contributed to the biochemical analysis; AS, TH, KTanizawa, TT, and TK assisted with either the radiological or pathological diagnoses of the study subjects; and TT contributed to the pathological evaluations. All authors participated in data interpretation, revisions of the manuscript, and final approval of the manuscript.

Acknowledgement
We would like to thank Dr. Tamaki Takahashi (Department of Respiratory Medicine, Japanese Red Cross Otsu Hospital) for assisting in data collection. The present study was partially supported by a Grant-in-Aid for scientific research (No. 25461156) from the Ministry of Education, Culture, Sports, Science and Technology, Japan. The present study was also supported by a Grant-in-Aid from the Japan Society for the Promotion of Science to TH. The present study was also supported by a research (No. 26461187). Grant-in Aid from the Japan Society for the Promotion of Science and Technology, Japan. The present study was also supported by a Grant-in-Aid for scientific research (No. 23461156) from the Ministry of Education, Culture, Sports, Science and Technology, Japan. The present study was also supported by a Grant-in-Aid for scientific research (No. 26461156) from the Ministry of Education, Culture, Sports, Science and Technology, Japan.

Received: 7 May 2015 Accepted: 20 September 2015
Published online: 29 September 2015

References
1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.
2. King Jr TE, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011;378:1949–61.
3. Ley B, Collard HR, King Jr TE. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183:431–40.
4. Wells AU, Behr J, Costabel U, Cotton V, Poletti V, Richeldi L. Hot of the breath: mortality as a primary end-point in IPF treatment trials; the best is the enemy of the good. Thorax. 2012;67:988–90.
5. King Jr TE, Albera C, Bradford WZ, Costabel U, du Bois RM, Leff JA, et al. All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials. Am J Respir Crit Care Med. 2014;189:825–31.
6. Ley B, Brown KK, Collard HR. Molecular biomarkers in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2014;307:L681–691.
7. Vij R, Noth I. Peripheral blood biomarkers in idiopathic pulmonary fibrosis. Transl Respir. 2012;159:218–27.
8. Sato H, Kurishima K, Iihikawa H, Ohtsuka M. Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases. J Intern Med. 2006;260:429–34.
9. Kindel BW, Brown KK, McCormack FX, Ix JH, Kevitsky A, Schwatz MI, et al. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest. 2009;135:1557–63.
10. Prasse A, Probst C, Bagargai E, Zissel G, Toews GB, Flaherty KR, et al. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009;179:71–73.
11. Richards TJ, Kaminski N, Barlaud F, Flavin S, Brodmerkel C, Horowitz D, et al. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012;185:567–72.
12. Pardo A, Selman M. Matrix metalloproteinases in aberrant fibrotic tissue remodeling. Proc Am Thorac Soc. 2006;3:383–8.
13. Dancer RC, Wood AM, Thickett DR. Metalloproteinases in idiopathic pulmonary fibrosis. Eur Respir J. 2011;38:1461–7.
14. Miechow S, Richter AG, O’Kane C, McKaley DF, Thickett DR. MMP expression and abnormal lung permeability are important determinants of outcome in IPF. Eur Respir J. 2009;33:37–84.
15. Rosas I, Richards TJ, Konishi K, Zhang Y, Gibson K, Lokshin AE, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med. 2008;5:e93.
16. Yu G, Kovkaraova-Nauzumovska E, Vata P, Panwani A, Kass D, Ruz V, et al. Matrix metalloproteinase-19 is a key regulator of lung fibrosis in mice and humans. Am J Respir Crit Care Med. 2012;186:552–62.
17. Orbe DA, Jara P, Martinez de Lizarrondo S, Calvayrac O, Rodriguez C, Martinez-Gonzalez J, et al. Metalloproteinases and atherothrombosis: MMP-10 mediates vascular remodeling promoted by inflammatory stimuli. Front Biosci. 2008;13:2916–21.
18. Kramper M, Blach W, Sasai T, Bugnon P, Rulicke T, Wolf E, et al. Activities of the matrix metalloproteinase stromelysin-2 (MMP-10) in matrix degradation and keratinocyte organization in wounded skin. Mol Biol Cell. 2004;15:5242–54.
19. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187:347–65.
20. Pellegrino R, Vieggi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26:468–68.
21. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:1117–73.
22. Technical recommendations and guidelines for bronchoalveolar lavage (BAL). Report of the European Society of Pneumology Task Group. Eur Respir J. 1989;2561–585.
23. Meyer KC, Raghu G, Baughman RP, Brown KK, Costabel U, du Bois RM, et al. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med. 2012;185:1004–14.
24. Limb GA, Matter K, Murphy G, Cambrey AD, Bishop PH, Morris GE, et al. Matrix metalloproteinase-1 associates with intracellular organelles and confers resistance to lamin A/C degradation during apoptosis. Am J Pathol. 2005;166:555–63.
25. Yamashita CM, Dolgonos L, Zemans RL, Young SK, Robertson J, Briones N, et al. Matrix metalloproteinase 3 is a mediator of pulmonary fibrosis. Am J Pathol. 2011;179:1733–45.
26. Zuo F, Kaminski N, Eguil E, Alland J, Yahhini Z, Ben-Dor A, et al. Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc Natl Acad Sci U S A. 2002;99:6292–7.

27. Song JW, Do KH, Jang SJ, Colby TV, Han S, Kim DS. Blood biomarkers MMP-7 and SP-A: predictors of outcome in idiopathic pulmonary fibrosis. Chest. 2013;142:1422–9.

28. Goulilou P, Jayson MI, Valat JP, Freemont AJ. Matrix metalloproteinases: the clue to intervertebral disc degeneration? Spine (Phila Pa 1976). 1998;23:1612–26.

29. Murphy G, Cockett MJ, Ward RV, Docherty AJ. Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan. A quantitative comparison of the activities of 95 kDa and 72 kDa gelatinases, stromelysins-1 and -2 and punctuated metalloproteinase (PUMP). Biochem J. 1991;277(Pt 1):277–9.

30. Nakamura H, Fujiy O, Chuchi E, Yamamoto E, Okada Y. Activation of the precursor of human stromelysin 2 and its interactions with other matrix metalloproteinases. Eur J Biochem. 1998;253:67–75.

31. Koller FL, Dozier EA, Nam KT, Swee M, Birkland TP, Parks WC, et al. Lack of MMP10 exacerbates experimental colitis and promotes development of inflammation-associated colonic dysplasia. Lab Invest. 2012;92:1749–59.

32. Garcia-Irigoyen O, Carotti S, Lataza MU, Uriarte I, Fernandez-Barrero MG, Elizabe M, et al. Matrix metalloproteinase-10 expression is induced during hepatic injury and plays a fundamental role in liver tissue repair. Liver Int. 2014;34:e257–270.

33. Zhang X, Zhu S, Luo G, Zheng L, Wei J, Zhu J, et al. Expression of MMP-10 in lung cancer. Anticancer Res. 2007;27:2791–5.

34. Deraz EM, Kudo Y, Yoshida M, Obayashi M, Tsunematsu T, Tani H, et al. MMP-10/stromelysin-2 promotes invasion of head and neck cancer. PLoS One. 2011;6, e25438.

35. Seargent JM, Loadman PM, Martin SW, Naylor B, Bibby MC, Gill JH. Expression of matrix metalloproteinase-10 in human bladder transitional cell carcinoma. Urology. 2005;65:815–20.

36. Kerkela E, Ala-aho R, Lohi J, Grenman R, M-Kähäri V, Saarialho-Kere U. Differential patterns of stromelysin-2 (MMP-10) and MT1-MMP (MMP-14) expression in epithelial skin cancers. Br J Cancer. 2001;84:659–69.

37. Miyata Y, Iwata T, Maruta S, Kanda S, Nishikido M, Koga S, et al. Expression of matrix metalloproteinase-10 in renal cell carcinoma and its prognostic role. Eur Urol. 2007;52:791–7.

38. Meyer E, Vollmer JY, Bovey R, Stanemokovic I, Matrix metalloproteinases 9 and 10 inhibit protein kinase C-potentiated, p53-mediated apoptosis. Cancer Res. 2005;65:4261–72.

39. Ma JY, Mercer RR, Barger M, Schwegler-Berry D, Scabilloni J, Ma JK, et al. Induction of pulmonary fibrosis by cerium oxide nanoparticles. Toxicol Appl Pharmacol. 2012;262:25–64.

40. Scabilloni JJ, Wang L, Antonini JM, Roberts JR, Castranova V, Mercer RR. Matrix metalloproteinase induction in fibrosis and fibrotic nodule formation due to silica inhalation. Am J Physiol Lung Cell Mol Physiol. 2005;288:L709–17.

41. Choi M, Cho WS, Han BS, Cho M, Kim SY, Yi JY, et al. Transient pulmonary fibrogenic effect induced by intratracheal instillation of ultrafine amorphous silica in A/J mice. Toxicol Lett. 2008;182:97–101.

42. Fernandez IE, Eickelberg O. The impact of TGF-beta on lung fibrosis: from targeting to biomarkers. Proc Am Thorac Soc. 2012;9:111–6.

43. Maher TM. Idiopathic pulmonary fibrosis: pathology of novel approaches to treatment. Clin Chest Med. 2012;33:69–83.

44. Kristic J, Santibanez JF. Transforming growth factor-beta and matrix metalloproteinases: functional interactions in tumor stroma-infiltrating myeloid cells. ScientificWorldJournal. 2014;2014:521754.

45. Ishikawa F, Miyoshi H, Nose K, Shibamura M. Transcriptional induction of MMP-10 by TGF-beta, mediated by activation of MEK/ERK and downregulation of class Ia HDACs. Oncogene. 2010;29:909–19.

46. Huh JW, Kim DS, Oh YM, Shim TS, Lim CM, Lee SO, et al. Is matrixmetalloproteinase-7 specific for idiopathic pulmonary fibrosis? Chest. 2008;133:110–6.

47. Vuorinen K, Myllaniemi M, Lammi L, Pirila P, Rytila P, Salmenkivi K, et al. Elevated matrilysin levels in bronchoalveolar lavage fluid do not distinguish idiopathic pulmonary fibrosis from other interstitial lung diseases. APMIS. 2007;115:969–75.

48. Moizadeh P, Krieg T, Hellmich M, Brinckmann J, Neumann E, Muller-Ladner U, et al. Elevated MMP-7 levels in patients with systemic sclerosis: correlation with pulmonary involvement. Exp Dermatol. 2011;20:770–3.

49. Shihab FS, Bennett WM, Yi H, Andoh TF. Pirfenidone treatment decreases transforming growth factor-beta 1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephotoxicity. Am J Transplant. 2002;2:111–9.